the efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-na？ve patients with type 2 diabetes mellitus a randomized controlled trial的疗效和安全性dipeptidyl peptidase-4抑制剂saxagliptin treatment-na ve 2型糖尿病患者的随机对照试验.pdfVIP

下载本文档

1
0
约8.4万字
约 12页
2017-09-12 发布于上海
举报
版权申诉

the efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-na？ve patients with type 2 diabetes mellitus a randomized controlled trial的疗效和安全性dipeptidyl peptidase-4抑制剂saxagliptin treatment-na ve 2型糖尿病患者的随机对照试验.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

the efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-na？ve patients with type 2 diabetes mellitus a randomized controlled trial的疗效和安全性dipeptidyl peptidase-4抑制剂saxagliptin treatment-na ve 2型糖尿病患者的随机对照试验

Frederich et al. Diabetology Metabolic Syndrome 2012, 4:36 DIABETOLOGY /content/4/1/36 METABOLIC SYNDROME RESEARCH Open Access The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial 1* 2 3 1 1 Robert Frederich , Robert McNeill , Niklas Berglind , Douglas Fleming and Roland Chen Abstract Background: The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks. Methods: 365 treatment-naïve patients with T2DM (HbA1c 7.0%– 10.0%) were treated with saxagliptin 2.5 mg q.A.M., saxagliptin 2.5 mg q.A.M. with possible titration to saxagliptin 5 mg, saxagliptin 5 mg q.A.M., saxagliptin 5 mg q.P. M., or placebo. After week 24, patients in all groups were eligible for titration to saxagliptin 10 mg based on HbA1c ≥7%, and all unrescued placebo patients began blinded metformin 500 mg/day. Rescue with open-label metformin was available for patients with inadequate glycemic control. Results: At week 24, placebo-subtracted mean HbA1c reduction from baseline (LOCF) was significantly greater in the saxagliptin treatment groups vs placebo, and remained greater through week 76. Serious adverse events (AEs) and discontinuations due to AEs were similar in saxagliptin and control groups; incidence of confirmed hypoglycemia was low acros